Patents by Inventor Raphael Mechoulam

Raphael Mechoulam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100222438
    Abstract: Novel methods and pharmaceutical compositions suitable for modulating bone growth and remodeling, preventing bone diseases, inducing bone growth or repair by cannabinoid receptor-mediated effects on bone cells is disclosed. Methods of identifying bone growth modulating agents are also disclosed.
    Type: Application
    Filed: February 23, 2010
    Publication date: September 2, 2010
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Itai Bab, Raphael Mechoulam, Andreas Zimmer, Esther Shohami
  • Patent number: 7759526
    Abstract: The present invention relates to cannabidiol derivatives and to pharmaceutical compositions comprising cannabidiol derivatives being antiinflammatory agents having analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity. The present invention also relates to a process for the preparation of cannabidiol derivatives. It also relates to the use of cannabidiol derivatives and of pharmaceutical compositions comprising same in the preparation of a medicament, in a method of the treatment of human beings with cannabidiol derivatives or with a pharmaceutical preparations comprising same.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: July 20, 2010
    Assignee: Yissum Research Development Company
    Inventors: Raphael Mechoulam, Susana Tchilibon, Ester Fride, Lumir Hanus, Aviva Breuer, Ruth Gallily
  • Patent number: 7749953
    Abstract: Novel methods and pharmaceutical compositions suitable for modulating bone growth and remodeling, preventing bone diseases, inducing bone growth or repair by cannabinoid receptor-mediated effects on bone cells is disclosed. Methods of identifying bone growth modulating agents are also disclosed.
    Type: Grant
    Filed: December 6, 2004
    Date of Patent: July 6, 2010
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Itai Bab, Raphael Mechoulam, Andreas Zimmer, Esther Shohami
  • Publication number: 20100158973
    Abstract: The present invention provides the use of a Cannabidiol (CBD) compound for the preparation of a pharmaceutical composition for treatment as well as for the prevention of at least one fundamental parameter affecting a vascular system selected from (a) the cardiovascular system; (b) the peripheral vascular system; or (c) a combination of (a) and (b); as well as pharmaceutical compositions and therapeutic methods for treating the above. A fundamental parameter may include blood/plasma lipid profile; atherosclerosis plaque load; size of heart scar; thickness of heart scar; and cardiac function in general. In accordance with a preferred embodiment the invention concerns treatment of heart scars as well as preventing the formation of heart scars.
    Type: Application
    Filed: March 13, 2007
    Publication date: June 24, 2010
    Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LlIMITED
    Inventors: Lola Weiss, Vardiella Meiner, Eran Leitersdorf, Shimon Slavin, Raphael Mechoulam, Ruth Gallily, Chaim Lotan, Ronen Durst, Thea Pugatsch
  • Publication number: 20100152238
    Abstract: Novel cannabinoid-derived quinone derivatives (quinonoid derivatives) having a substituted hydroxyl group, pharmaceutical compositions comprising same and uses thereof as anti-proliferative agents, are provided.
    Type: Application
    Filed: March 5, 2008
    Publication date: June 17, 2010
    Applicant: Yissum Research Development Company of The Hebrew University of Jerusalem
    Inventors: Raphael Mechoulam, Natalya Kogan
  • Publication number: 20100099756
    Abstract: The described subject matter relates to the use of incensole, incensole acetate, and derivatives thereof, for the treatment, prevention or amelioration of diseases or conditions, including inflammatory-associated conditions; a disease or condition where neuroprotection is required; and a disease or condition selected from depression, anxiety, obsessive compulsive behaviors, deterioration in cognitive function, and deterioration in neurobehavioral function. Pharmaceutical compositions and method of treatment, prevention or amelioration of the above-mentioned diseases or conditions are also provided.
    Type: Application
    Filed: November 29, 2007
    Publication date: April 22, 2010
    Applicants: ARIEL-UNIVERSITY RESEARCH DEVELOPMENT COMPANY LTD.
    Inventors: Arik Moussaieff, Raphael Mechoulam, Ester Fride, Esther Shohami, Yinon Ben Neriah, Ruth Gallily
  • Publication number: 20100022631
    Abstract: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.
    Type: Application
    Filed: April 24, 2009
    Publication date: January 28, 2010
    Applicants: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services & Development Ltd., Aristotle University of Thessaloniki
    Inventors: Elliot BERRY, Yosefa Avraham, Raphael Mechoulam, Yaron Ilan, Yossi Dagon, Iddo Magen, Nicholas Grigoriadis, Theofilos Poutachidis
  • Publication number: 20100004244
    Abstract: The present invention relates to ligands of the peripheral cannabinoid receptor CB2, especially (+)-?-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for promoting, inducing and enhancing neurogenesis including neural cell regeneration. In particular, pharmaceutical compositions of the invention will be useful for preventing, alleviating or treating neurological injuries or damages to the CNS or the PNS associated with physical injury, ischemia, neurodegenerative disorders, certain medical procedures or medications, tumors, infections, metabolic or nutritional disorders, cognition or mood disorders, and various medical conditions associated with neural damage or destruction.
    Type: Application
    Filed: June 27, 2007
    Publication date: January 7, 2010
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Ismael Galve-Roperh, Manuel Guzman, Raphael Mechoulam, Javier Palazuelos, Tania Aguado
  • Publication number: 20080275135
    Abstract: Disclosed are synthetic cannabinoids, namely resorcinol derivatives, which reduce blood pressure without having psychotropic effects. Pharmaceutical compositions for the treatment of high blood pressure related conditions, as well as methods of treating the same utilizing as active agent the compounds of the invention are also disclosed herein. Preferred active compounds are those which bear a long side chain on the C5 position and a terpenoid chain on the C2 position.
    Type: Application
    Filed: June 20, 2005
    Publication date: November 6, 2008
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW
    Inventors: Raphael Mechoulam, Yehoshua Maor, Lumir Hanus, Michal Horowitz
  • Publication number: 20080221339
    Abstract: Methods of converting cannabidiol to ?8-tetrahydrocannabinol or ?9-tetrahydrocannabinol are described. The described methods produce higher yields and higher purity compared to prior art methods.
    Type: Application
    Filed: March 20, 2008
    Publication date: September 11, 2008
    Inventors: G. R. Barrie Webster, Leonard P. Sarna, Raphael Mechoulam
  • Patent number: 7407753
    Abstract: The present invention uncovers a highly significant association of SNPs in the CNR2 locus, encoding the cannabinoid receptor 2 protein, with osteoporosis. Methods and kits for determining predisposition to osteoporosis, improving diagnosis in individuals suspected of having osteoporosis are provided. Also provided a method of identifying a putative osteoporosis-causing genetic mutation in a subject.
    Type: Grant
    Filed: May 24, 2004
    Date of Patent: August 5, 2008
    Assignees: Yissum Research Development Company of the HebrewUniversityofJerusalem, Institut National de la Sante et de la Recherche Medicale
    Inventors: Andreas Zimmer, Meliha Karsak, Marie-Christine De Vernejoul, Itai Bab, Esther Shohami, Raphael Mechoulam
  • Patent number: 7399872
    Abstract: Methods of converting cannabidiol to ?8-tetrahydrocannabinol or ?9-tetrahydrocannabinol are described. The described methods produce higher yields and higher purity compared to prior art methods.
    Type: Grant
    Filed: March 7, 2002
    Date of Patent: July 15, 2008
    Inventors: G. R. Barrie Webster, Leonard P. Sarna, Raphael Mechoulam
  • Patent number: 7214716
    Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)- type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: May 8, 2007
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
  • Publication number: 20070099987
    Abstract: Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.
    Type: Application
    Filed: February 16, 2005
    Publication date: May 3, 2007
    Inventors: Lola Weiss, Michael Zeira, Raphael Mechoulam, Shimon Slavin, Ruth Gallily
  • Publication number: 20070082954
    Abstract: Cannabinoid derivatives are known for their functions in the central as well as peripheral nervous system. The present invention describes some novel (+)-cannabidiol (CBD) derivatives, and their selective activity in the peripheral and not in the central nervous system. Thus, it is an object of the invention to provide the use of (+)-CBD derivatives as analgesics, anti-inflammatory and anti-diarrheal agents.
    Type: Application
    Filed: September 8, 2004
    Publication date: April 12, 2007
    Inventors: Raphael Mechoulam, Ester Fride
  • Publication number: 20070049645
    Abstract: The present invention relates the use of certain cannabidiol derivatives and of their dimethyl heptyl homologs (CBD-DMH) in the treatment of nausea, in particular chemotherapy-induced nausea, and of anti vomiting activity. The present invention relates also to the use of said cannabidiol derivatives being part of a pharmaceutical composition.
    Type: Application
    Filed: June 16, 2006
    Publication date: March 1, 2007
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Raphael Mechoulam, Linda Parker, Aviva Breuer
  • Publication number: 20050260608
    Abstract: The present invention uncovers a highly significant association of SNPs in the CNR2 locus, encoding the cannabinoid receptor 2 protein, with osteoporosis. Methods and kits for determining predisposition to osteoporosis, improving diagnosis in individuals suspected of having osteoporosis are provided. Also provided a method of identifying a putative osteoporosis-causing genetic mutation in a subject.
    Type: Application
    Filed: May 24, 2004
    Publication date: November 24, 2005
    Inventors: Andreas Zimmer, Meliha Karsak, Marie-Christine De Vernejoul, Itai Bab, Esther Shohami, Raphael Mechoulam
  • Publication number: 20050165118
    Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
    Type: Application
    Filed: January 27, 2005
    Publication date: July 28, 2005
    Applicant: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
  • Publication number: 20050137159
    Abstract: Novel methods and pharmaceutical compositions suitable for modulating bone growth and remodeling, preventing bone diseases, inducing bone growth or repair by cannabinoid receptor-mediated effects on bone cells is disclosed. Methods of identifying bone growth modulating agents are also disclosed.
    Type: Application
    Filed: December 6, 2004
    Publication date: June 23, 2005
    Inventors: Itai Bab, Raphael Mechoulam, Andreas Zimmer, Esther Shohami
  • Patent number: 6903137
    Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: June 7, 2005
    Assignee: Yissum Research Development Co. of the Hebrew University of Jerusalem
    Inventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon